

## DAFTAR PUSTAKA

- Afzal Ashaie, M. dan Hoque Chowdhury, E. (2016) “Cadherins: The Superfamily Critically Involved in Breast Cancer,” *Current Pharmaceutical Design*, 22(5), hal. 616–638. doi: 10.2174/138161282205160127095338.
- Allred, D. C. (2010) “Ductal carcinoma in situ: Terminology, classification, and natural history,” *Journal of the National Cancer Institute - Monographs*, (41), hal. 134–138. doi: 10.1093/jncimonographs/lgq035.
- Alsaleem, M. *et al.* (2019) “The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts,” *Modern Pathology*, 32(7), hal. 967–976. doi: 10.1038/s41379-019-0209-9.
- American Cancer Society (2017) *Breast Cancer Facts & Figures 2017-2018*. Atlanta: American Cancer Society, Inc.
- Baker, A. T., Zlobin, A. dan Osipo, C. (2014) “Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer,” *Frontiers in Oncology*, 4(NOV). doi: 10.3389/fonc.2014.00360.
- Baranwal, S. dan Alahari, S. K. (2009) “Molecular mechanisms controlling E-cadherin expression in breast cancer,” *Biochemical and Biophysical Research Communications*, 384(1), hal. 6–11. doi: 10.1016/j.bbrc.2009.04.051.
- Barlow, W. E. *et al.* (2002) “Performance of Diagnostic Mammography for Women With Signs or Symptoms of Breast Cancer,” *JNCI: Journal of the National Cancer Institute*, 94(15), hal. 1151–1159. doi: 10.1093/jnci/94.15.1151.
- Brzozowska, A. *et al.* (2012) “Evaluation of prognostic parameters of E-cadherin status in breast cancer treatment,” *Annals of Agricultural and Environmental Medicine*, 19(3), hal. 541–546.
- Burstein, H. J. *et al.* (2014) “Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update,” *Journal of Clinical Oncology*, 32(21), hal. 2255–2269. doi: 10.1200/JCO.2013.54.2258.
- Cano, A. *et al.* (2000) “The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression,” *Nature Cell Biology*, 2(2), hal. 76–83. doi: 10.1038/35000025.

- Carey, L. A. *et al.* (2007) “The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes,” *Clinical Cancer Research*, 13(8), hal. 2329–2334. doi: 10.1158/1078-0432.CCR-06-1109.
- Chen, C. *et al.* (2020) “Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations,” *The Oncologist*, 25(1). doi: 10.1634/theoncologist.2019-0123.
- Colakoglu, M. K. *et al.* (2018) “Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy,” *European Journal of Breast Health*, 14(2), hal. 100–104. doi: 10.5152/ejbh.2018.3780.
- Coleman, M. P. *et al.* (2008) “Cancer survival in five continents: a worldwide population-based study (CONCORD),” *The Lancet Oncology*, 9(8), hal. 730–756. doi: 10.1016/S1470-2045(08)70179-7.
- Corso, G., Bonanni, B. dan Veronesi, P. (2018) “Tumor inactivation of E-cadherin: a new tool for breast cancer treatment?,” *Annals of Translational Medicine*, 6(S1), hal. S6–S6. doi: 10.21037/atm.2018.08.45.
- Curado, M. P. (2011) “Breast cancer in the world: Incidence and mortality,” *Salud Publica de Mexico*. doi: 10.1590/S0036-36342011000500005.
- Dai, X. *et al.* (2016) “Cancer hallmarks, biomarkers and breast cancer molecular subtypes,” *Journal of Cancer*, 7(10), hal. 1281–1294. doi: 10.7150/jca.13141.
- Darby, S. *et al.* (2011) “Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials,” *The Lancet*, 378(9804), hal. 1707–1716. doi: 10.1016/S0140-6736(11)61629-2.
- Darwin, E., Elfi, E. F. dan Elvira, D. (2017) *Endotel: Fungsi dan Disfungsi*. Padang: Andalas University Press.
- Davies, C. *et al.* (2013) “Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial,” *The Lancet*, 381(9869), hal. 805–816. doi: 10.1016/S0140-6736(12)61963-1.
- Devi, C. R. B., Tang, T. S. dan Corbex, M. (2012) “Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia,” *International Journal of*

- Cancer*. doi: 10.1002/ijc.27527.
- Dey, N., Leyland-Jones, B. dan De, P. (2016) “HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies,” in Dey, N., De, P., dan Leyland-Jones, B. (ed.) *PI3K-mTOR in Cancer and Cancer Therapy*. 1 ed. Cham: Springer International Publishing (Cancer Drug Discovery and Development), hal. 231–261.
- Dieci, M. V. *et al.* (2014) “Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities,” *The Oncologist*, 19(8), hal. 805–813. doi: 10.1634/theoncologist.2014-0108.
- Dittrich, A. *et al.* (2014) “The HER2 Signaling Network in Breast Cancer—Like a Spider in its Web,” *Journal of Mammary Gland Biology and Neoplasia*, 19(3–4), hal. 253–270. doi: 10.1007/s10911-014-9329-5.
- Dowsett, M. *et al.* (2010) “Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen,” *Journal of Clinical Oncology*, 28(3), hal. 509–518. doi: 10.1200/JCO.2009.23.1274.
- Duru, N. *et al.* (2014) “Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society,” *Journal of Cancer Research and Clinical Oncology*, 140(1), hal. 1–14. doi: 10.1007/s00432-013-1494-1.
- Dyanti, G. A. R. dan Suariyani, N. L. P. (2016) “FAKTOR-FAKTOR KETERLAMBATAN PENDERITA KANKER PAYUDARA DALAM MELAKUKAN PEMERIKSAAN AWAL KE PELAYANAN KESEHATAN,” *Jurnal Kesehatan Masyarakat*, 11(2), hal. 276. doi: 10.15294/kemas.v11i2.3742.
- Edge, S.B. *et al.* (2017) *AJCC Cancer Staging Manual, AJCC Cancer Staging Manual*. Diedit oleh M. B. Amin *et al.* Cham: Springer International Publishing. doi: 10.1007/978-3-319-40618-3.
- ElMoneim, H. M. A. dan Zaghloul, N. M. (2011) “Expression of e-cadherin, n-cadherin and snail and their correlation with clinicopathological variants: An immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt,” *Clinics*. doi: 10.1590/S1807-59322011001000015.
- Fan, L., Goss, P. E. dan Strasser-Weippl, K. (2015) “Current Status and Future

- Projections of Breast Cancer in Asia,” *Breast Care*. doi: 10.1159/000441818.
- Fidler, I. J. (2003) “The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited,” *Nature Reviews Cancer*.
- Fink, M. Y. dan Chipuk, J. E. (2013) “Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers,” *Genes and Cancer*, 4(5–6), hal. 187–195. doi: 10.1177/1947601913488598.
- Gall, T. M. H. dan Frampton, A. E. (2013) “Gene of the month: E-cadherin (CDH1),” *Journal of Clinical Pathology*, 66(11), hal. 928–932. doi: 10.1136/jclinpath-2013-201768.
- Ghoncheh, M., Pournamdar, Z. dan Salehiniya, H. (2016) “Incidence and Mortality and Epidemiology of Breast Cancer in the World,” *Asian Pacific Journal of Cancer Prevention*.
- Giuliano, A. E. *et al.* (2017) “Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual,” *CA: A Cancer Journal for Clinicians*, 67(4), hal. 290–303. doi: 10.3322/caac.21393.
- Glajcar, A. *et al.* (2017) “The relationship between breast cancer molecular subtypes and mast cell populations in tumor microenvironment,” *Virchows Archiv*, 470(5), hal. 505–515. doi: 10.1007/s00428-017-2103-5.
- Goldhirsch, A. *et al.* (2013) “Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013,” *Annals of Oncology*, 24(9), hal. 2206–2223. doi: 10.1093/annonc/mdt303.
- Green, J. *et al.* (2011) “Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk,” *The Lancet Oncology*, 12(8), hal. 785–794. doi: 10.1016/S1470-2045(11)70154-1.
- Gross, R. E. (2000) “Breast cancer: risk factors, screening, and prevention.,” *Seminars in oncology nursing*, 16(3), hal. 176–184. doi: 10.1053/sonc.2000.8110.
- Gruver, A. M., Portier, B. P. dan Tubbs, R. R. (2011) “Molecular pathology of breast cancer the journey from traditional practice toward embracing the complexity of a molecular classification,” *Archives of Pathology and*

- Laboratory Medicine*, 135(5), hal. 544–557. doi: 10.1043/2010-0734-RAIR.1.
- Hagemann, I. S. (2016) “Molecular testing in breast cancer: A guide to current practices,” *Archives of Pathology and Laboratory Medicine*, 140(8), hal. 815–824. doi: 10.5858/arpa.2016-0051-RA.
- Hajra, K. M., Chen, D. Y. S. dan Fearon, E. R. (2002) “The SLUG zinc-finger protein represses E-cadherin in breast cancer,” *Cancer Research*, 62(6), hal. 1613–1618.
- Hammer, C., Fanning, A. dan Crowe, J. (2008) “Overview of breast cancer staging and surgical treatment options.,” *Cleveland Clinic Journal of Medicine*, 75(Suppl\_1), hal. S10–S10. doi: 10.3949/ccjm.75.Suppl\_1.S10.
- Harahap, W. A. (2014) *Metilasi Promoter Breast Cancer Gene 1 dan Hubungannya dengan Faktor Prognostik Karsinoma Payudara Sporadik Premenopause pada Etnis Minang*. Universitas Andalas.
- Harahap, W. A. dan Khambri, D. (2018) “Outcomes of breast cancer treatment in West Sumatera-Indonesia,” *European Journal of Cancer*, 92, hal. S27. doi: 10.1016/s0959-8049(18)30307-1.
- He, L. *et al.* (2019) “The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity,” *Cancer Management and Research*, 11, hal. 5765–5775. doi: 10.2147/CMAR.S213663.
- Hoda, S. A. *et al.* (2014) *Rosen’s breast pathology: Fourth edition, Rosen’s Breast Pathology: Fourth Edition*.
- Hollestelle, A. *et al.* (2013) “Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer,” *Breast Cancer Research and Treatment*, 138(1), hal. 47–57. doi: 10.1007/s10549-013-2415-3.
- Horne, H. N. *et al.* (2018) “E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium,” *Scientific Reports*, 8(1), hal. 6574. doi: 10.1038/s41598-018-23733-4.
- Hu, Q. P. *et al.* (2016) “Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer,” *International Journal of Cancer*, 138(12), hal.

- 2804–2812. doi: 10.1002/ijc.29982.
- Ingthorsson, S. *et al.* (2016) “HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR,” *Oncogene*, 35(32), hal. 4244–4255. doi: 10.1038/onc.2015.489.
- International Agency for Research on Cancer (2007) “Shift-work, painting and fire-fighting,” in *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*. Lyon: International Agency for Research on Cancer. doi: 10.1136/jcp.48.7.691-a.
- Iqbal, Nida dan Iqbal, Naveed (2014) “Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications,” *Molecular Biology International*, 2014, hal. 1–9. doi: 10.1155/2014/852748.
- Januardi, Y. *et al.* (2019) “Relationship Among Expression of E-Cadherin and HER-2/Neu with Metastasis in Breast Cancer,” *International Journal of Surgery and Medicine*, (0), hal. 1. doi: 10.5455/ijsm.ecadherin-her2-metastatic-breast-cancer.
- Jatiluhur, I. M. *et al.* (2014) “Hubungan antara HER-2/neu dan Ki-67 dengan Respons Kemo-terapi Neoadjuvan pada Karsinoma Payudara Lanjut Lokal,” *Majalah Patologi Indonesia*, 23(3), hal. 32–40.
- Jemal, A. dan Fedewa, S. A. (2012) “Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women?,” *Breast Cancer Research and Treatment*, 135(3), hal. 867–873. doi: 10.1007/s10549-012-2214-2.
- Jemndahl, L., Isakson, P. dan Baeckström, D. (2005) “c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation,” *International Journal of Oncology*, 27(2), hal. 439–448. doi: 10.3892/ijo.27.2.439.
- Jolly, M. K. *et al.* (2017) “Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?,” *Molecular Oncology*, 11(7), hal. 739–754. doi: 10.1002/1878-0261.12084.
- Kakarala, M. *et al.* (2010) “Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis,” *BMC Cancer*, 10(1), hal. 191. doi: 10.1186/1471-2407-10-191.

- Kalluri, R. dan Weinberg, R. A. (2009) "The basics of epithelial-mesenchymal transition," *Journal of Clinical Investigation*, 119(6), hal. 1420–1428. doi: 10.1172/JCI39104.
- Khambri, D. (2015) *Hubungan Ekspresi Androgen Receptor dengan Faktor Prognostik Karsinoma Payudara di Sumatera Barat*. Universitas Andalas.
- Kondov, B. *et al.* (2018) "Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients," *Open Access Macedonian Journal of Medical Sciences*, 6(6), hal. 961–967. doi: 10.3889/oamjms.2018.231.
- Koo, M. M. *et al.* (2017) "Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis," *Cancer Epidemiology*, 48, hal. 140–146. doi: 10.1016/j.canep.2017.04.010.
- Kyoto Encyclopedia of Genes and Genomes (2018) *Breast cancer - Homo sapiens (human)*. Tersedia pada: <https://www.genome.jp/kegg/kegg2.html> (Diakses: 19 Januari 2020).
- Lantz, P. M. dan Mullen, J. (2015) "The National Breast and Cervical Cancer Early Detection Program: 25 Years of public health service to low-income women," *Cancer Causes and Control*, 26(5), hal. 653–656. doi: 10.1007/s10552-015-0565-9.
- Lester, S. (2015) "The Breast," in Kumar, V., Abbas, A., dan Aster, J. (ed.) *Robbins and Cotran Pathologic Basis of Disease*. 9th ed. Elsevier, hal. 1051–1064.
- Li, C. I., Malone, K. E. dan Daling, J. R. (2002) "Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older," *Cancer Epidemiology Biomarkers and Prevention*.
- Li, Z. *et al.* (2017) "Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis," *Oncotarget*, 8(10), hal. 16445–16455. doi: 10.18632/oncotarget.14860.
- Lin, C. *et al.* (2014) "Distinct Clinicopathological Features and Prognosis of Emerging Young-Female Breast Cancer in an East Asian Country: A Nationwide Cancer Registry-Based Study," *The Oncologist*, 19(6), hal. 583–591. doi: 10.1634/theoncologist.2014-0047.

- Lodish, H. *et al.* (2003) *Molecular Cell Biology*. New York: W. H. Freeman.
- Loh *et al.* (2019) “The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges,” *Cells*, 8(10), hal. 1118. doi: 10.3390/cells8101118.
- Lu, M. *et al.* (2014) “E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis,” *Molecular Cell*, 54(6), hal. 987–998. doi: 10.1016/j.molcel.2014.04.029.
- Lumintang, L. M. *et al.* (2015) “Profil Pasien Kanker Payudara di Rumah Sakit Onkologi Surabaya, 2014,” *Indonesian Journal of Cancer*, 9(3), hal. 105–110.
- Meiners, S. *et al.* (1998) “Role of morphogenetic factors in metastasis of mammary carcinoma cells,” *Oncogene*, 16(1), hal. 9–20. doi: 10.1038/sj.onc.1201486.
- Mendonsa, A. M., Na, T. Y. dan Gumbiner, B. M. (2018) “E-cadherin in contact inhibition and cancer,” *Oncogene*, 37(35), hal. 4769–4780. doi: 10.1038/s41388-018-0304-2.
- Morin, P. J. *et al.* (1997) “Activation of  $\beta$ -catenin-Tcf signaling in colon cancer by mutations in  $\beta$ -catenin or APC,” *Science*, 275(5307), hal. 1787–1790. doi: 10.1126/science.275.5307.1787.
- Nagafuchi, A. (2001) “Molecular architecture of adherens junctions,” *Current Opinion in Cell Biology*, 13(5), hal. 600–603. doi: 10.1016/S0955-0674(00)00257-X.
- National Breast Cancer Foundation (2019) *Breast cancer anatomy and how cancer starts*. Tersedia pada: <https://nbcf.org.au/about-breast-cancer/diagnosis/breast-cancer-anatomy/> (Diakses: 20 Januari 2020).
- Ng, C. H. *et al.* (2011) “Comparison of breast cancer in Indonesia and Malaysia - A clinico-pathological study between dharmais cancer centre Jakarta and university Malaya medical centre, Kuala Lumpur,” *Asian Pacific Journal of Cancer Prevention*.
- Nillson, G. M. A. *et al.* (2014) “Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition,” *International Journal of Oncology*, 45(1), hal. 82–94. doi: 10.3892/ijo.2014.2424.
- Oeffinger, K. C. *et al.* (2015) “Breast cancer screening for women at average risk:



- 2015 Guideline update from the American cancer society,” *JAMA - Journal of the American Medical Association*, 314(15), hal. 1599–1614. doi: 10.1001/jama.2015.12783.
- Oktarina, M. Z. *et al.* (2012) “Kesesuaian Ekspresi E-Cadherin pada Karsinoma Duktal dan Lobular Payudara,” *Majalah Patologi Indonesia*, 21(3). Tersedia pada:  
<http://majalahpatologiindonesia.com/p/index.php/patologi/article/view/50>.
- Ozmen, V., Ozmen, T. dan Dogru, V. (2019) “Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer,” *European Journal of Breast Health*, 15(3), hal. 141–146. doi: 10.5152/ejbh.2019.4890.
- Pagani, O. *et al.* (2014) “Adjuvant exemestane with ovarian suppression in premenopausal breast cancer,” *New England Journal of Medicine*, 371(2), hal. 107–118. doi: 10.1056/NEJMoa1404037.
- Pang, H. *et al.* (2013) “Prognostic values of osteopontin-c, E-cadherin and  $\beta$ -catenin in breast cancer,” *Cancer Epidemiology*. doi: 10.1016/j.canep.2013.08.005.
- Panigoro, S. S., Karsono, R. dan Sari, L. (2017) “E-cadherin and Vimentin as Predictors of Resistance to Preoperative Systemic Therapy in Patients with Advanced Breast Cancer,” *eJournal Kedokteran Indonesia*, 4(3), hal. 149–155. doi: 10.23886/ejki.4.7109.149-55.
- Pareja, F., Pines, G. dan Yarden, Y. (2015) “The EGFR/ERBB receptor family,” in Wheeler, D. L. dan Yarden, Y. (ed.) *Receptor Tyrosine Kinases: Family and Subfamilies*. Cham: Springer International Publishing, hal. 107–164. doi: 10.1007/978-3-319-11888-8\_4.
- Pece, S. dan Gutkind, J. S. (2000) “Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation,” *Journal of Biological Chemistry*, 275(52), hal. 41227–41233. doi: 10.1074/jbc.M006578200.
- Rakha, E. A. *et al.* (2005) “E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance,” *Histopathology*, 46(6), hal. 685–693. doi: 10.1111/j.1365-2559.2005.02156.x.
- Rakha, E. A. *et al.* (2010) “Clinical and Biological Significance of E-cadherin Protein Expression in Invasive Lobular Carcinoma of the Breast,” *The*

- American Journal of Surgical Pathology*, 34(10), hal. 1472–1479. doi: 10.1097/PAS.0b013e3181f01916.
- Romond, E. H. *et al.* (2005) “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” *New England Journal of Medicine*, 353(16), hal. 1673–1684. doi: 10.1056/NEJMoa052122.
- Rosa, M. (2015) “Advances in the molecular analysis of breast cancer: Pathway toward personalized medicine,” *Cancer Control*, 22(2), hal. 211–219. doi: 10.1177/107327481502200213.
- Ross, J. S. *et al.* (2009) “The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine,” *The Oncologist*, 14(4), hal. 320–368. doi: 10.1634/theoncologist.2008-0230.
- Rosso, M. *et al.* (2017) “E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness,” *PLoS ONE*, 12(9). doi: 10.1371/journal.pone.0184439.
- Van Roy, F. dan Berx, G. (2008) “The cell-cell adhesion molecule E-cadherin,” *Cellular and Molecular Life Sciences*, 65(23), hal. 3756–3788. doi: 10.1007/s00018-008-8281-1.
- Russell, C. A. (2014) “Personalized medicine for breast cancer: It is a new day!,” *American Journal of Surgery*, 207(3), hal. 321–325. doi: 10.1016/j.amjsurg.2013.10.016.
- Sakhdari, A., Hutchinson, L. dan Oscar, E. F. (2015) “Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy,” in Khan, A. *et al.* (ed.) *Precision Molecular Pathology of Breast Cancer*. 1 ed. New York, NY: Springer (Molecular Pathology Library), hal. 119–136.
- Seddiki, R. *et al.* (2018) “Force-dependent binding of vinculin to  $\alpha$ -catenin regulates cell-cell contact stability and collective cell behavior,” *Molecular Biology of the Cell*, 29(4), hal. 380–388. doi: 10.1091/mbc.E17-04-0231.
- Sharma, V. R. *et al.* (2019) “Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer,” *Seminars in Cancer Biology*, 59, hal. 133–146. doi: 10.1016/j.semcancer.2019.08.005.
- Singh, D. *et al.* (2015) “Association of symptoms and breast cancer in population-

- based mammography screening in Finland,” *International Journal of Cancer*, 136(6), hal. E630–E637. doi: 10.1002/ijc.29170.
- Singhai, R. *et al.* (2011) “E-Cadherin as a diagnostic biomarker in breast cancer,” *North American Journal of Medical Sciences*, 3(5), hal. 227–233. doi: 10.4297/najms.2011.3227.
- Takeichi, M. (1977) “Functional correlation between cell adhesive properties and some cell surface proteins,” *Journal of Cell Biology*, 75(2), hal. 464–474. doi: 10.1083/jcb.75.2.464.
- Al Tamimi, D. M. *et al.* (2010) “Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study,” *BMC Cancer*, 10(1), hal. 223. doi: 10.1186/1471-2407-10-223.
- Tamimi, R. M. *et al.* (2012) “Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer,” *Breast Cancer Research and Treatment*, 131(1), hal. 159–167. doi: 10.1007/s10549-011-1702-0.
- Tang, D. *et al.* (2012) “The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer,” *Medical Oncology*, 29(2), hal. 526–533. doi: 10.1007/s12032-011-9948-2.
- Tevaarwerk, A. J. *et al.* (2013) “Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years,” *Cancer*, 119(6), hal. 1140–1148. doi: 10.1002/cncr.27819.
- The American Cancer Society (2019) *What Is Breast Cancer?* Tersedia pada: <https://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html> (Diakses: 20 Januari 2020).
- Union for International Cancer Control (UICC) (2019) *New Global Cancer Data: GLOBOCAN 2018*. Tersedia pada: <https://www.uicc.org/news/new-global-cancer-data-globocan-2018> (Diakses: 13 Oktober 2019).
- Voudouri, K. *et al.* (2015) “Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease,” *Analytical Cellular Pathology*, 2015, hal. 1–10. doi: 10.1155/2015/975495.
- Vu, T. dan Claret, F. X. (2012) “Trastuzumab: Updated mechanisms of action and resistance in breast cancer,” *Frontiers in Oncology*, 2 JUN. doi:

10.3389/fonc.2012.00062.

- Wang, M. *et al.* (2016) “N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells,” *International Journal of Oncology*, 48(2), hal. 595–606. doi: 10.3892/ijo.2015.3270.
- Wells, A., Yates, C. dan Shepard, C. R. (2008) “E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas,” *Clinical and Experimental Metastasis*, 25(6), hal. 621–628. doi: 10.1007/s10585-008-9167-1.
- White, J. *et al.* (2011) “Breast Conservation Surgery: State of the Art,” *International Journal of Breast Cancer*, 2011, hal. 1–10. doi: 10.4061/2011/107981.
- White, M. C. *et al.* (2014) “Disparities in cancer mortality and incidence among American Indians and Alaska natives in the United States,” *American Journal of Public Health*, 104(SUPPL. 3). doi: 10.2105/AJPH.2013.301673.
- Widodo, I. *et al.* (2014) “Clinicopathological features of Indonesian breast cancers with different molecular subtypes,” *Asian Pacific Journal of Cancer Prevention*. doi: 10.7314/APJCP.2014.15.15.6109.
- Wolff, A. C. *et al.* (2007) “American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer,” *Journal of Clinical Oncology*, 26(1), hal. 118–145. doi: 10.1200/JCO.2006.09.2775.
- Wolff, A. C. *et al.* (2018) “Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update,” *Journal of Clinical Oncology*, 36(20), hal. 2105–2122. doi: 10.1200/JCO.2018.77.8738.
- World Health Organization (2018) *Breast cancer*. Tersedia pada: <https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/> (Diakses: 13 Oktober 2019).
- Yamashita, N. *et al.* (2018) “Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin With Regard to Invasion and Metastasis of Breast Cancer,” *Clinical Breast Cancer*, 18(5), hal. e1003–

- e1009. doi: 10.1016/j.clbc.2018.02.002.
- Yang, L. *et al.* (2018) “Significance and prognosis of epithelial-cadherin expression in invasive breast carcinoma,” *Oncology Letters*, 16(2), hal. 1659–1665. doi: 10.3892/ol.2018.8836.
- Yap, Y.-S. *et al.* (2019) “Insights Into Breast Cancer in the East vs the West,” *JAMA Oncology*, 5(10), hal. 1489. doi: 10.1001/jamaoncol.2019.0620.
- Yates, L. R. *et al.* (2017) “Genomic Evolution of Breast Cancer Metastasis and Relapse,” *Cancer Cell*, 32(2), hal. 169-184.e7. doi: 10.1016/j.ccell.2017.07.005.
- Younis, L. K., El Sakka, H. dan Haque, I. (2007) “The Prognostic Value of E-cadherin Expression in Breast Cancer.,” *International journal of health sciences*.
- Yulianti, I., Santoso, H. dan Sutiningsih, D. (2016) “FAKTOR-FAKTOR RISIKO KANKER PAYUDARA (STUDI KASUS PADA RUMAH SAKIT KEN SARAS SEMARANG),” *Jurnal Kesehatan Masyarakat Universitas Diponegoro*.
- Zaha, D. C. *et al.* (2019) “Luminal Versus Non-luminal Breast Cancer CDH1 Immunohistochemical Expression,” *Revista de Chimie*, 70(2), hal. 465–469. doi: 10.37358/RC.19.2.6936.
- Zaidel-Bar, R. (2013) “Cadherin adhesome at a glance,” *Journal of Cell Science*, 126(2), hal. 373–378. doi: 10.1242/jcs.111559.
- Zeng, P. *et al.* (2019) “HER2 upregulates ATF4 to promote cell migration via activation of ZEB1 and downregulation of E-cadherin,” *International Journal of Molecular Sciences*, 20(9). doi: 10.3390/ijms20092223.